Prostratin: An overview

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 13, 2015, Pages 1122-1130

  Miana, Ghulam Abbas ^a   Riaz, Muhammad ^b   Shahzad Ul Hussan, Syed ^c   Paracha, Rehan Zafar ^d   Paracha, Usman Zafar ^a  

^a RIPHAH INTERNATIONAL UNIVERSITY   (Pakistan)

^b UNIVERSITY OF AZAD JAMMU AND KASHMIR   (Pakistan)

^c LAHORE UNIVERSITY OF MANAGEMENT SCIENCES   (Pakistan)

^d GOMAL UNIVERSITY   (Pakistan)

Author keywords

Promising drug candidate; Prostartin

Indexed keywords

PHORBOL ESTER DERIVATIVE; PROSTRATIN; PROTEIN KINASE C; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; PHORBOL ESTER;

CARCINOGENESIS; CHEMICAL STRUCTURE; ENDOCYTOSIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; IMMUNE RESPONSE; INTERNALIZATION; KAPOSI SARCOMA; MEMORY T LYMPHOCYTE; REVIEW; SYNTHESIS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS LATENCY; VIRUS LOAD; ANGIOSPERM; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HIV INFECTIONS; HUMAN; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOSPERMS; ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DISCOVERY; HIV INFECTIONS; HIV-1; HUMANS; NEOPLASMS; PHORBOL ESTERS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; VIRUS INTERNALIZATION; VIRUS LATENCY;

EID: 84947771562     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150511154108     Document Type: Review

References (65)

1. [1] Powderly, W. G., Landay, A., & Lederman, M. M. Recovery of the Immune System with Anti-retroviral therapy: The End of Opportunism? JAMA, 1998, 280, 72-77.
2. [2] Schmit, J. C., Cogniaux, J., Hermans, P., Van Vaeck, C., Sprecher, S., Van Remoortel, B., et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an effeciently replicating human immunodeficiency virus type-1 patient strain. J. Infect. Dis., 1998, 174, 962-968.
3. [3] Chun, T. W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1998, 387(6629), 183-188.
4. [4] Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1998, 278, 1295-1300.
5. [5] Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A., et al. Recovery of Replication competent HIV despite prolonged suppression of plasma viremia. Science, 1997, 278, 1291-1295.
6. [6] Yang, Q. E. Eradication of HIV in infected patients: Some potential approaches. Med. Sci. Monitor, 2004, 10 (7), RA155-RA165.
7. [7] Chun, T. W., Engel, D., Mizell, S. B., Hallahan, C. W., Fischette, M., Park, S., et al. Effect of Interleukin-2 on the pool of latently infected, resting CD4+ T-cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat. Med., 1999, 5, 651-655.
8. [8] van Praag, R. M., Prins, J. M., Roos, M. T., Schellekens, P. T., Ten Berge, I. J., Yong, S. L., et al. OKT-3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long lasting CD4+ T cell depletion. J. Clin. Immunol., 2001, 21(3), 218-226.
9. [9] Brooks, D. G., Kitchen, S. G., Kitchen, C. M., Scripture Adams, D. D., & Zack, J. A. Generation of HIV latency during thymopoiesis. Nat. Med., 2001, 7, 459-464.
10. [10] Siliciano, J.D., Lai, J., Callender, M., Pitt, E., Zhang, H., Margolick, J. B., et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis., 2007, 195(6), 833-836.
11. [11] Cox, P. A. Saving the ethnopharmacological heritage of Samoa. J. Ethnopharmacol., 1993, 38(2-3), 181-188.
12. [12] Cox, P. A. Ensuring equitable benefits: The falealupo Covenant and the isolation of Anti-Viral Drug Prostratin from a Samoan Medicinal Plant. Pharmaceut. Biol. (Formerly International Journal of Pharmacognosy), 2001, 39(1), 33-40.
13. [13] Cox, P. A., & Heinrich, M. Ethnobotany and drug development. Pharmaceut. News, 2001, 8(3), 55-59.
14. [14] Gustafson, K. R., Cardellina, J. H., McMahon, J. B., Gulakowski, R. J., Ishitoya, J., Szallasi, Z., et al. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J. Med. Chem., 1992, 35(11), 1978-1986.
15. [15] Cashmore, A. R., Seelye, R. N., Cain, B. F., Moch, H., Schmidt, R., & Hecker, E. The structure of prostratin. A toxic tetracyclic diterpene ester from Pimelea prostrata. Tetrahed. Lett., 1976, 1737-1738.
16. [16] Miana, G. A., Bashir, M., & Evans, F. J. Isolation of Prostratin from Euphorbia cornigera. Planta Medica, 1985, 51(4), 353-354.
17. [17] Johnson, H. E., Banack, S. A., & Cox, P. A. Variability in Content of the Anti-AIDS Drug Candidate Prostratin in Samoan Populations of Homalanthus nutans. J. Nat. Prod., 2008, 71(12), 2041-2044.
18. [18] Johnson, H., Banack, S.A., & Cox, P.A. Paper presented at the 48th annual meeting of society for economic botany. www.econbot.org/_organization_/07_annual_meetings/meeting_ab stracts/2007.php. Chicago, Illinois, United States: Economic Botany. (2007, June 4-7).
19. [19] Wender, P. A., Kee, J. M., & Warrington, J. M. Practical Synthesis of Prostratin, DPP and their Analogs, Adjuvant leads against Latent HIV. Science, 2008, 320, 649.
20. [20] Cairnes, D. A., Mirvish, S. S., Wallcave, L., Nagel, D. L., & Smith, J. W. A rapid method for isolating phorbol from croton oil. Cancer Lett., 1981, 14(1), 85-91.
21. [21] Gschwendt, M., & Hecker, E. Tumor promoting compounds from Euphorbia cooperi di- and tri-esters of lo-hydroxy-H-deoxyphorbol. Tetrahed. Lett., 1970, 11, 567-570.
22. [22] Hirota, M., Suttajit, M., Suguri, H., Endo, Y., Shudo, K., Wongchai, V., et al. A new tumor promoter from the seed oil of Jatropha curcas L., an intramolecular diester of 12-deoxy-16-hydroxyphorbol. Cancer Res.,1988, 48(20), 5800-5804.
23. [23] Mellor, H., & Parker, P. J. The extended protein kinase C superfamily. J. Biochem., 1998, 281-292.
24. [24] Nishizuka, Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J., 1995, 9(7), 484-496.
25. [25] Dempsey, E. C., Newton, A. C., Mochly-Rosen, D., Fields, A. P., Reyland, M. E., Insel, P. A., et al. Protein Kinase C isozymes and the regulation of diverse cell responses. Amer. J. Physiol., 2000, 279, 429-438.
26. [26] Clemens, M. J., Trayner, I., & Menaya, J. The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. J. Cellular Sci., 1992, 103, 881-887.
27. [27] Parolini, I., Topa, S., Sorice, M., Pace, A., Ceddia, P., Montesoro, E., et al. Phorbol ester induced disruption of the CD4-Lck complex occurs within a detergent resistant microdomain of the plasma membrane. Involvement of the translocation of activated protein kinase C isoforms. J. Biol. Chem., 1999, 274, 14176-14187.
28. [28] Pelchen-Matthews, A., Armea, J. E., & Marsh, M. Internalization and recycling of CD4 transfected into HsLa and NIH3t3 cells. EMBO J., 1989, 8, 3641-3649.
29. [29] Signoret, N., Oldridge, J., Pelchen-Matthews, A., Klasse, P. J., Tran, T., Brass, L. F., et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J. Cell Biol., 1997, 139, 651-654.
30. [30] Signoret, N., Rosenlike, M. M., Klasse, P. J., Schwartz, T. W., Malim, M. H., Hoxie, J. A., et al. Differential regulation of CXCR4 and CCR5 endocytosis. J. Cell Sci., 1998, 111, 2819-2830.
31. [31] Segal, A., Van Duuren, B. L., & Mate, U. The identification of Phorbolmyristate acetate as a new metabolite of phorbol myristate acetate in mouse skin. Cancer Res., 1975, 35, 2154-2159.
32. [32] Gulakowski, R. J., McMohan, J. B., Buckheit, R. W., Gustafson, K. R., & Boyd, M. R. Antireplicative and anticytopathic activities of prostratin, a non-tumor promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res., 1997, 33, 87-97.
33. [33] Kulkosky, J., Culnan, D. M., Roman, J., Dornadula, G., Schnell, M., Boyd, M. R., et al. Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood, 2001, 98, 3006-3015.
34. [34] Hezareh, M., Moukil, M. A., Szanto, I., Pondarzewski, M., Mouche, S., Cherix, N., et al. Mechanisms of HIV receptor and coreceptor down regulation by prostratin: role of conventional and novel PKC isoforms. Antiviral Chem. Chemother., 2004, 15, 207-222.
35. [35] Trushin, S. A., Pennington, K. N., Carmona, E. M., Asin, S., Savoy, D. N., Billadeau, D. D., et al. Protein kinase C-alpha (PKCalpha) acts upstream of PKC-theta to activate IkB kinase and NFkB in T-lymphocytes. Mol.Cell Biol., 2003, 23, 7068-7081.
36. [36] Biancotto, A., Grivel, J. C., Gondois-Rey, F., Vigne, L. R., Brown, S., Margolis, L. B., et al. Dual role of Prostratin in Inhibition of Infection and Reactivation of Human Immunodeficiency Virus from Latency in Primary Blood Lymphocytes and Lymphoid Tissue. J. Virol., 2004, 10507-10515.
37. [37] Williams, S. A., Chen, L. F., Kwon, H. F., Bisgrove, D., & Verdin, E. G. Prostratin Antagonizes HIV Latency by Activating NF-kB. J. Biol. Chem., 2004, 279(40), 42008-42017.
38. [38] Trushin, S. A., Bren, G. D., Asin, S., Pennington, K. N., Paya, C. V., & Badley, A. D. Human Immunodeficiency Virus Reactivation by Phorbol Esters or T-Cell Receptor Ligation Requires bokh PKCalpha and PKC-theta. J. Virol., 2005, 9821-9830.
39. [39] Mosior, M., & Newton, A. C. Mechanism of interaction of protein kinase C with phorbol esters. Reversibility and nature of membrane association. J. Biol. Chem., 1995, 270, 25526-25533.
40. [40] Ventura, C., & Maioli, M., Protein kinase C control of gene expression. Crit.Rev. Eukaryotic Gene Exp., 2001, 11, 243-267.
41. [41] Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A., Baseler, M., et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc. Nat. Acad. Sci., 1997, 13193-13197.
42. [42] Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., et al. Long term follow up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T-cells. Nat. Med., 2003, 9, 727-728.
43. [43] Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., et al. Latent infection of CD4+ T-cells provide a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med., 1999, 5(5), 512-517.
44. [44] Zhang, L., Chung, C., Hu, B. S., He, T., Guo, Y., Kim, A. J., et al. Genetic characterization of rebounding HIV-1 after cessation of highly active anti-retroviral therapy. J. Clin. Invest., 2000, 106(7), 839-845.
45. [45] Pomerantz, R.J. Eliminating HIV-1 reservoirs. Curr. Opin. Investigat. Drugs, 2002, 3, 1133-1137.
46. [46] Forsdyke, D. R. Programmed activation of T-lymphocytes. A theoretical basis for short term treatment of AIDS with azidothymidine. Med. Hypoth., 1991, 34(1), 24-27.
47. [47] Jones, K. A., & Peterlin, B. M. Control of RNA initiation and elongation at the HIV-1 promoter. Ann. Rev. Biochem., 1994, 63, 717-743.
48. [48] Leonard, J., Parrott, C., Buckler-White, A. J., turner, W., Ross, E. K., Martin, M. A., et al. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J. Virol., 1989, 63(11), 4919-4924.
49. [49] Jordan, A., Bisgrove, D., & Verdin, E. HIV reproducibly establishes a latent after acute infection of T-cells in vitro. EMBOJ., 2003, 22, 1868-1877.
50. [50] Korin, Y. D., Brooks, D. G., Brown, S., Korotzer, A., & Zack, J. A. Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency. J. Virol., 2002, 8118-8123.
51. [51] Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature, 1997, 387 (6629), 188-191.
52. [52] Schmidt, A., Henninghausen, A., & Siebenlist, U. Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T-cells can be blocked by cyclosporin A in a signal dependent manner. J. Virol., 1990, 64(8), 4037-4041.
53. [53] Sung, T.L., & Rice, A.P. Effects of Prostratin on Cyclin t1/P-TEFb function and the gene expression profile in primary resting CD4+T-cells. Retrovirology, 2006, 3, 66.
54. [54] Wityrouw, M., Pannecouque, C., Fikkert, V., Hantson, A., Van Remoortel, B., Hezareh, M., et al. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. Antiviral Chem. Chemother., 2003, 14(6), 321-328.
55. [55] Tobina, G.J., Ennisa, W.H., Clantonb, D.J., & Gonda, M.A. Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture based assay. Antiviral Res., 1996, 33, 21-31.
56. [56] Brown, H. J., McBride, W. H., Zack, J. A., & Sun, R. Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma associated herpesvirus. Antiviral Ther., 2005, 10(6), 745-751.
57. [57] Nishizuka, Y. The role of Protein Kinase C in cell surface signal transduction and tumor promotion. Nature, 1984, 693-698.
58. [58] Nishizuka, Y. Studies and perspectives of protein kinase C. Science, 1986, 305-312.
59. [59] Nishizuka, Y. The Molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature, 1988, 661-665.
60. [60] Nishizuka, Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science, 1992, 607-614.
61. [61] Blumberg, P. M. Protein kinase C as the receptor for the phorbol ester tumor promoters:Sixth Rhoads Memorial Award Lecture. Cancer Res., 1988, 48, 1-8.
62. [62] Blumberg, P. M. Complexities of the protein kinase C pathway. Mol. Carcinogen., 1991, 4(5), 339-344.
63. [63] Szallasi, Z., Krsmanovic, L., & Blumberg, P. M. Non-promoting 12-Deoxyphorbol 13-Esters Inhibit Phorbol 12-Myristate 13-Acetate Induced tumor promotion in CD-I Mouse Skin. Cancer Res., 1993, 53, 2507-2512.
64. [64] Rullas, J., Bermejo, M., Garcia-Perez, J., Beltan, M., Gonzalez, N., Hezareh, M., et al. Prostratin induces HIV activation and down regulates HIV receptors in peripheral blood lymphocytes. Antiviral Ther., 2004, 9 (4), 545-554.
65. [65] Wang, H., Zhu, X., Zhu, Y., Liu, J., Hu, X., Yu Wang, Y., Peng, S., Chen, Y., Chen, R., Ding, F. and Liu, R. Protein Kinase D3 Is Essential for Prostratin-Activated Transcription of Integrated HIV-1 Provirus Promoter via NF-!B Signaling Pathway. BioMed. Res. Intl., 2014, 2014, 968027.